Evidence record · ER-RETATRUTIDE-WEIGHT-014
Does retatrutide produce weight loss in clinical trials?
Retatrutide produces weight loss in adults with obesity or overweight
Retatrutide produced substantial weight loss in a phase 2 randomised trial of adults with obesity or overweight. That supports efficacy within the trial’s population and follow-up, but retatrutide remains investigational. It is not UK-authorised, long-term benefit-risk is still being studied, and online products are not the trial medicine.
Claim boundary
What this verdict covers
The verdict covers weight change in the phase 2 trial population after a defined investigational product. It does not imply approval, routine clinical availability or verified consumer supply.
- Compound
- Retatrutide
- Population
- Adults enrolled in a phase 2 obesity trial
- Outcome
- Percentage change in body weight
- Record ID
- ER-RETATRUTIDE-WEIGHT-014
Evidence synthesis
What the research can support
The 48-week phase 2 study enrolled 338 adults and reported dose-related weight reduction compared with placebo. Larger phase 3 programmes are needed to refine effectiveness, safety, discontinuation effects and subgroup estimates.
Why the confidence is moderate
Phase 2 evidence is promising but smaller and less mature than an approval package. Gastrointestinal adverse effects and longer-term outcomes remain important.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-RETATRUTIDE-WEIGHT-014 addresses one bounded question: Does retatrutide produce weight loss in clinical trials?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Relevant human, the verdict is Supported and confidence is Moderate. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Phase 2 retatrutide obesity trial | The randomised trial found substantial, dose-related weight loss over 48 weeks. | Phase 2 results do not constitute marketing authorisation. | 10 August 2026 |
| TRIUMPH phase 3 programme record | The registry documents ongoing confirmatory development. | A registry entry does not provide final efficacy or safety results. | 10 August 2026 |
| MHRA products database | The database is the current source for UK marketing authorisations. | It does not list trial participation as an authorisation. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Retatrutide for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
The 48-week phase 2 study enrolled 338 adults and reported dose-related weight reduction compared with placebo. Larger phase 3 programmes are needed to refine effectiveness, safety, discontinuation effects and subgroup estimates. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Retatrutide authorised in the UK for this use?
Retatrutide remains an investigational medicine and has no UK marketing authorisation. Trial evidence cannot authorise or verify a product sold online. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
As an investigational, non-approved pharmacological substance, retatrutide may fall within WADA S0. Athletes should obtain current sport-specific advice. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
Completed phase 3 trials, regulator decisions, full label information and longer-term cardiovascular, metabolic and safety follow-up. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation